

May 2019

Osteoarthritis (OA)



- [We initiated our first pivotal Phase 3 study for lorecivivint \(the generic name for SM04690\)](#)

Oncology (ONC)



- The FDA has allowed the Investigational New Drug (IND) application for our second oncology compound, SM09419, focusing on hematological cancers

Alzheimer's Disease (AD)



- [Our Phase 1 single ascending dose \(SAD\) study for SM07883 is under way](#)

Idiopathic Pulmonary Fibrosis (IPF)



- [We successfully completed our Phase 1 multiple ascending dose \(MAD\) study](#)